Abivax remains unsold despite intense biotech merger buzz
The French drugmaker Abivax, known for its ulcerative colitis candidate obefazimod, has yet to secure a buyer amid a surge in biotech M&A activity.
Abivax continues to operate independently while industry observers note a flood of merger and acquisition deals in the biotech sector. The company’s lead product, obefazimod, is viewed as having strong commercial potential, prompting speculation about interest from large pharmaceutical firms. However, no definitive transaction has been announced, leaving investors uncertain about the company’s future direction.
Why it matters
Investors and the biotech market watch Abivax’s status closely as it could signal broader trends in pharma consolidation.
In this story
Abivaxobefazimodulcerative colitisbiotech mergerspharma acquisitioninvestor uncertainty
